DrugPatentWatch Database Preview
LITHOTABS Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Lithotabs, and what generic alternatives are available?
Lithotabs is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in LITHOTABS is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
US ANDA Litigation and Generic Entry Outlook for Lithotabs
A generic version of LITHOTABS was approved as lithium carbonate by HIKMA on January 29th, 1982.
Summary for LITHOTABS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 92 |
| Patent Applications: | 101 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LITHOTABS at DailyMed |
Synonyms for LITHOTABS
| 2BMD2GNA4V |
| 554-13-2 |
| ACMC-209lmw |
| AK00285039 |
| AKOS015904647 |
| ANGC-554-13-2 |
| ANW-32310 |
| B7705 |
| C07964 |
| Camcolit |
| Candamide |
| Carbolith |
| Carbolithium |
| Carbolithium IFI |
| Carbolitium |
| Carbonic Acid Dilithium Salt |
| Carbonic acid lithium salt |
| Carbonic acid lithium salt (Li2CO3) |
| Carbonic acid, dilithium salt |
| Carbonic acid, lithium salt |
| Carbonic acid, lithium salt (1:2) |
| CCRIS 3153 |
| Ceglution |
| CHEBI:6504 |
| CHEMBL1200826 |
| CLi2O3 |
| CP 15467-61 |
| CP-15,467-61 |
| CP-15467-61 |
| CP-1546761 |
| CTK1G9703 |
| D00801 |
| DB14509 |
| Dilithium carbonate |
| Dilithium Carbonate, Dilithium Salt, Carbonic Acid |
| dilithium trioxidocarbonate |
| DTXSID1023784 |
| EC 209-062-5 |
| EINECS 209-062-5 |
| Eskalith |
| Eskalith (TN) |
| Eskalith CR |
| Eutimin |
| FT-0627895 |
| GK3300 |
| HSDB 3351 |
| Hypnorex |
| I494 |
| KS-0000025D |
| KSC269O0H |
| L0224 |
| Li2 (C O3) |
| Li2CO3 |
| Limas |
| Liskonum |
| Litard |
| Lithane |
| Lithea |
| Lithicarb |
| Lithinate |
| Lithionate |
| LITHIUM CARBONATE |
| Lithium carbonate (2:1) |
| Lithium carbonate (JP17/USP) |
| Lithium carbonate (Li2CO3) |
| Lithium carbonate [USAN:JAN] |
| Lithium carbonate [USAN:USP:JAN] |
| Lithium Carbonate Nanoparticles |
| Lithium carbonate, 98+%, for analysis |
| Lithium carbonate, 99.999%, (trace metal basis), extra pure |
| Lithium carbonate, 99%, pure |
| Lithium carbonate, 99+%, ACS reagent |
| Lithium carbonicum |
| Lithium Phasal |
| Lithium QD |
| Lithium, Reference Standard Solution |
| Lithizine |
| Litho-Carb |
| Lithobid |
| Lithobid (TN) |
| Lithonate |
| Liticar |
| LS-88061 |
| Manialith |
| Maniprex |
| MFCD00011084 |
| Micalith |
| Neurolepsin |
| NSC-16895 |
| Pfi-lithium |
| Pfl-Lithium |
| Phasal |
| Plenur |
| Priadel |
| Q410174 |
| Quilonorm |
| Quilonum retard |
| RTR-019539 |
| Teralithe |
| Teralithe [French] |
| TR-019539 |
| TRA0065195 |
| UNII-2BMD2GNA4V |
| XGZVUEUWXADBQD-UHFFFAOYSA-L |
US Patents and Regulatory Information for LITHOTABS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | LITHOTABS | lithium carbonate | TABLET;ORAL | 016980-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
